Nama's AI scorecard currently rates Stoke Therapeutics Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does STOK report earnings?

Stoke Therapeutics's next scheduled report is on Mar 15, 2027. Analysts expect EPS of -$1.20.

What is the STOK price target?

The median analyst price target from 13 analysts is $43.00, with a range of $35.00 – $60.00.

Is STOK Shariah compliant?

Nama's AAOIFI-style screen reads Stoke Therapeutics as Can't Tell. A figure the screen needs is missing, so it can't tell.

Nama Insights

Stoke Therapeutics (STOK)

Healthcare · Biotechnology · NASDAQ

Stoke Therapeutics (STOK) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.74B and a free-cash-flow yield of 2.9%. Over the most recent reported fiscal year, revenue grew 404.5%. Nama's AI scorecard rates it Sell, 2.8 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 2.8/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Middle · +8.1% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-34.0%

How far the last close sits under the highest price of the past five years.

Market cap	$1.74B
Trailing P/E	—
Price / book	4.8
Price / sales	60.3
FCF yield	2.9%
Dividend yield	—
Gross margin	100.0%
Operating margin	-686.9%
Net margin	0.0%
Revenue growth (YoY)	+404.5%
Revenue growth (3-yr annual)	+145.9%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.3
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

STOK earnings

Next report: Mar 15, 2027 (Q4 2026, EPS estimate -$1.20). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 29, 2026	-$1.08	-$0.91	-18.7%	$11.26M
Q2 2026	Aug 3, 2026	-$0.93	-$0.78	-19.2%	$9.32M
Q1 2026	May 7, 2026	-$0.79	-$0.82	+3.7%	$6.23M
Q4 2025	Mar 16, 2026	-$0.97	-$0.74	-31.1%	$1.40M

STOK analyst price target

Median target $43.00 from 13 analysts, ranging $35.00 – $60.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live STOK data on Nama Insights →

STOK FAQ

Is STOK a buy?: Nama's AI scorecard currently rates Stoke Therapeutics Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does STOK report earnings?: Stoke Therapeutics's next scheduled report is on Mar 15, 2027. Analysts expect EPS of -$1.20.
What is the STOK price target?: The median analyst price target from 13 analysts is $43.00, with a range of $35.00 – $60.00.
Is STOK Shariah compliant?: Nama's AAOIFI-style screen reads Stoke Therapeutics as Can't Tell. A figure the screen needs is missing, so it can't tell.